Valuation: EnteroMedics Inc

Market Cap 15.93M 13.67M 12.76M 11.71M 22.02M 1.52B 22.38M 151M 58.96M 764M 59.82M 58.52M 2.53B P/E 2026 *
-3.22x
P/E 2027 * -2.48x
Enterprise Value 15.93M 13.67M 12.76M 11.71M 22.02M 1.52B 22.38M 151M 58.96M 764M 59.82M 58.52M 2.53B EV / Sales 2026 *
106x
EV / Sales 2027 * 63.7x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 129K 120K 110K 207K 14.34M 211K 1.42M 555K 7.19M 563K 551K 23.77M 250K 214K 200K 184K 345K 23.9M 351K 2.36M 925K 11.98M 939K 918K 39.62M
Net income -4.89M -4.19M -3.92M -3.59M -6.76M -467M -6.87M -46.22M -18.1M -234M -18.36M -17.96M -775M -7.77M -6.66M -6.22M -5.71M -10.74M -743M -10.91M -73.43M -28.75M -372M -29.17M -28.54M -1.23B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-